Patents Examined by Zohreh Fay
  • Patent number: 9999674
    Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 19, 2018
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9993471
    Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 12, 2018
    Inventors: Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
  • Patent number: 9988400
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 5, 2018
    Assignee: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
  • Patent number: 9987247
    Abstract: The present invention relates to a benzbromarone or different pharmaceutically acceptable crystals thereof, or pharmaceutically acceptable solvates, salts, esters, ethers or clathrates thereof, or use of a pharmaceutical composition comprising any of the above in preparation of drugs, application thereof being for preparation of drugs for treating and preventing vertebrae cervicales diseases or lumbar disk herniation (LDH) in human.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: June 5, 2018
    Inventor: Li Liu
  • Patent number: 9987254
    Abstract: Ophthalmic composition for the correction of presbyopia. Composition consisting of 2% Pilocarpine, characterized by being diluted to 1% with sterile Balanced Salt Solution (BSS), obtaining 1% pilocarpine (2.5 ml)+bromfenac, 1.8 mgrs of bromfenac (2.5 ml)+sterile Balanced Salt Solution (BSS) (2.5 ml), finally obtaining eye drops of 7.5 ml. It is also possible to obtain a 1.5% and 2% pilocarpine.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: June 5, 2018
    Inventors: Jose Vincent Rodriguez Hernandez, Humberto Carreras Diaz
  • Patent number: 9981959
    Abstract: Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: May 29, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Barbara J. Brandhuber, Yutong Jiang, Gabrielle R. Kolakowski, Shannon L. Winski
  • Patent number: 9980922
    Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 29, 2018
    Assignee: ZeaVision LLC
    Inventor: Dennis L. Gierhart
  • Patent number: 9968679
    Abstract: The present invention provides a stable and clear aqueous liquid preparation containing (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and benzalkonium chloride represented by the formula: [C6H5CH2N(CH3)2R]Cl wherein R is an alkyl group having 8-18 carbon atoms.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: May 15, 2018
    Inventors: Yuko Shikamura, Yuka Higashimura
  • Patent number: 9962334
    Abstract: The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 8, 2018
    Assignee: Novartis AG
    Inventors: Brett E. Thomes, Stephen J. Van Noy, Chi-Chun Tsai
  • Patent number: 9957226
    Abstract: The invention provides compounds for use in treating microbial infection in an animal. Example compounds include Pyridin-3-ylmethyl (4-((2-aminophenyl)-carbamoyl)benzyl)carbamate (“Entinostat”). The compounds can act via induction of the innate antimicrobial peptide defense system, and stimulation of autophagy.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: May 1, 2018
    Assignee: Akthelia Pharmaceuticals
    Inventors: Roger Stromberg, Hakan Ottoson, Birgitta Agerberth, Gudmundur Gudmundsson, Erica Miraglia, Frank Nylen
  • Patent number: 9949926
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 24, 2018
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • Patent number: 9943520
    Abstract: Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: April 17, 2018
    Inventors: Celine Decaudin, Vincent Rogue
  • Patent number: 9936715
    Abstract: Compositions and methods for lowering counts of pathogenic microorganisms in food products such as ready to eat meat and poultry products are disclosed. In various embodiments, the compositions and methods comprise antimicrobial compositions with one or more essential oils added.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 10, 2018
    Inventors: Richard Hull, Mo Toledo, Romeo Toledo
  • Patent number: 9913474
    Abstract: The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose; dextrose; glycerin; propylene glycol; ribose; triose; tetrose; erythrose; threose; pentose; arabinose; ribulose; xylose; xylulose; lyxose; hexose; allose; altrose; fructose; galactose; glucose; gulose; idose; mannose; sorbose; talose; tagatose; adlose; ketose; heptose; sedoheptulose; monosaccharides; disaccharides; sugar alcohols; xylitol; and polyol.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 13, 2018
    Assignee: FXS Ventures, LLC
    Inventor: Francis X. Smith
  • Patent number: 9913813
    Abstract: Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-HT receptors, such as tramadol. The aqueous compositions may for example be used as artificial tears, and as general ophthalmic lubricants for treating conditions such as dry eye or blepharitis. Further compositions combine ophthalmologicallyactive agents, such as pharmaceuticals, with opioids, such as tramadol in particular. These compositions may be used to treat the eye while reducing pain or discomfort that would normally be produced by administering these particular pharmaceuticals to the eye, and increasing the efficacy of the pharmaceuticals.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: March 13, 2018
    Assignee: Optosolve Research & Development Limited
    Inventor: Anant Sharma
  • Patent number: 9907826
    Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 6, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Peter A. Simmons, Joseph G. Vehige
  • Patent number: 9901580
    Abstract: A method comprising the step of: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of pterygium and pinguecula.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 27, 2018
    Inventor: Moshe Rogosnitzky
  • Patent number: 9895375
    Abstract: The present invention relates to a composition containing riboflavin and a sesamin-class compound(s). This composition may incorporate a sesamin-class compound(s) in such an amount that the proportion (weight ratio) of its total quantity to the total quantity of riboflavin taken as unity is no more than 4.5, and it has the advantage that the analgesic and anti-fatigue actions of riboflavin are synergistically improved by ingestion of riboflavin in combination with a sesamin-class compound(s). The composition of the present invention provides compositions, in particular, pharmaceuticals as well as foods and beverages that are safe to humans, animals, etc., and can therefore be ingested for a continued period, and which have far superior effects to those of conventional foods having an analgesic or anti-fatigue action.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 20, 2018
    Inventors: Daisuke Takemoto, Norifumi Tateishi, Yoshiko Ono, Kayo Saito, Akifumi Maeda
  • Patent number: 9895366
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: February 20, 2018
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Xu
  • Patent number: 9889088
    Abstract: The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: February 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, Daniel W. Gil, John E. Donello